The proposed UW CFAR is organized around 6 core units: Administration (including information transfer/publications and research training); clinical and molecular retrovirology; immunology, clinical research; biostatistics and epidemiology (including International AIDS Research and AIDS Registry); and non- human primate research. Two additional core units, behavioral sciences research and radiological imaging research, are envisioned via separate funding in future years. Over 75 faculty staff investigators of the proposed CFAR participate in active or pending research grants directly related to AIDS, HIV, or SIV and many of these also have other active grants in closely related fields such as non-primate retrovirology, molecular/cellular immunology, and other STDs. Ten distinct AIDS related themes have been identified, many involving parallel research in humans and non-human primates. The proposed CFAR would help coordinate this research to ensure efficient use of primates in research most relevant to human infection. Six active and two pending institutional post-doctoral research or clinical training grants at the UW are AIDS related. The process of planning this proposal has helped to coordinate the new allocations of 7450 sq. ft. of lab space to basic research on HIV and SIV. The CFAR would fund alteration, renovation, and equipping of a portion of these labs on the UW campus and at Fred Hutchinson Cancer Research Center. Planning for relocation of the HMC AIDS Clinic and the NIAID ACTU is already funded and underway. The CFAR would fund creation and co-location of a CFAR Clinical Research unit, including clinical and epidemiologic research trainees at the same site as the AIDS clinic and ACTU.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI027757-05S1
Application #
3101062
Study Section
Special Emphasis Panel (SRC (41))
Project Start
1988-09-30
Project End
1994-02-28
Budget Start
1992-09-01
Budget End
1994-02-28
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wagner, Anjuli D; Shah, Seema K; Njuguna, Irene N et al. (2018) Financial Incentives to Motivate Pediatric HIV Testing-Assessing the Potential for Coercion, Inducement, and Voluntariness. J Acquir Immune Defic Syndr 78:e15-e18
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Smith, Robert A; Wu, Vincent H; Zavala, Christopher G et al. (2018) In Vitro Antiviral Activity of Cabotegravir against HIV-2. Antimicrob Agents Chemother 62:
Stekler, Joanne D; Violette, Lauren R; Niemann, Lisa et al. (2018) Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. Open Forum Infect Dis 5:ofy197
Golob, Jonathan L; Stern, Joshua; Holte, Sarah et al. (2018) HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients. AIDS 32:2113-2118
Katz, David A; Golden, Matthew R; Hughes, James P et al. (2018) HIV Self-Testing Increases HIV Testing Frequency in High-Risk Men Who Have Sex With Men: A Randomized Controlled Trial. J Acquir Immune Defic Syndr 78:505-512
Pyra, Maria; Anderson, Peter L; Hendrix, Craig W et al. (2018) Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS 32:1891-1898
Dombrowski, Julia C; Golden, Matthew R; Barbee, Lindley A et al. (2018) Patient Disengagement From an HIV Preexposure Prophylaxis Program in a Sexually Transmitted Disease Clinic. Sex Transm Dis 45:e62-e64
Heller, Madeleine; Roberts, Sarah T; Masese, Linnet et al. (2018) Gender-Based Violence, Physiological Stress, and Inflammation: A Cross-Sectional Study. J Womens Health (Larchmt) 27:1152-1161
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372

Showing the most recent 10 out of 1275 publications